
==== Front
Front MicrobiolFront MicrobiolFront. Microbiol.Frontiers in Microbiology1664-302XFrontiers Media S.A. 10.3389/fmicb.2018.01437MicrobiologyMini ReviewLaboratory-Based and Point-of-Care Testing for MSSA/MRSA Detection in the Age of Whole Genome Sequencing van Belkum Alex 1*Rochas Olivier 21Data Analytics Unit, bioMérieux, La Balme-les-Grottes, France2Strategic Intelligence, Business Development Direction, bioMérieux, Marcy-l'Étoile, FranceEdited by: Richard Vernon Goering, Creighton University School of Medicine, United States

Reviewed by: Yan Q. Xiong, UCLA David Geffen School of Medicine, United States; Paul Douglas Fey, University of Nebraska Medical Center, United States

*Correspondence: Alex van Belkum, ashleykrista@example.com article was submitted to Antimicrobials, Resistance and Chemotherapy, a section of the journal Frontiers in Microbiology

29 6 2018 2018 9 143725 3 2018 11 6 2018 Copyright © 2018 van Belkum and Rochas.2018van Belkum and RochasThis is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.Staphylococcus aureus is an opportunistic pathogen of animals and humans that is capable of both colonizing and infecting its eukaryotic host. It is frequently detected in the clinical microbiology routine laboratory. S. aureus is capable of acquiring antibiotic resistance traits with ease and, given its rapid global dissemination, resistance to meticillin in S. aureus has received extensive coverage in the popular and medical press. The detection of meticillin-resistant versus meticillin-susceptible S. aureus (MRSA and MSSA) is of significant clinical importance. Detection of meticillin resistance is relatively straightforward since it is defined by a single determinant, penicillin-binding protein 2a', which exists in a limited number of genetic variants carried on various Staphylococcal Cassette Chromosomes mec. Diagnosis of MRSA and MSSA has evolved significantly over the past decades and there has been a strong shift from culture-based, phenotypic methods toward molecular detection, especially given the close correlation between the presence of the mec genes and phenotypic resistance. This brief review summarizes the current state of affairs concerning the mostly polymerase chain reaction-mediated detection of MRSA and MSSA in either the classical laboratory setting or at the point of care. The potential diagnostic impact of the currently emerging whole genome sequencing (WGS) technology will be discussed against a background of diagnostic, surveillance, and infection control parameters. Adequate detection of MSSA and MRSA is at the basis of any subsequent, more generic antibiotic susceptibility testing, epidemiological characterization, and detection of virulence factors, whether performed with classical technology or WGS analyses.

Staphylococcus aureusMSSAMRSAmolecular testingpoint of carenext generation sequencingwhole genome sequencesHorizon 202010.13039/501100007601675412
==== Body
Introduction
Detection of infectious agents and their diseases is performed through a wide array of diagnostic methodologies. These range from in silico methods assessing host' susceptibility to colonization and infection (Suh et al., 2018) to direct or indirect detection of the pathogen itself. The latter tests are collectively known as in vitro diagnostics (IVD) and their execution requires a qualified laboratory environment and highly educated technicians and (clinical) microbiologists. Next to the laboratory-based tests there are also more simple formats that should be safe to use outside of the laboratory by trained non-professionals at the point-of-need (PoN) or point-of-care (PoC). The more popular diagnostic tools are increasingly molecular in nature, having speed, specificity, and sensitivity superior to those of more classical, culture-based technologies. Molecular tests are based on different principles of which direct hybridization is among the most ancient. In addition, several different nucleic acid amplification technologies (NAATs) have been implemented [see Muldrew (2009) for a review]. Post-amplification processing often includes DNA fragment analysis and/or sequencing. Such tests are mostly aiming at detection and identification of disease-invoking bacterial species. Of note, primary detection and identification of micro-organisms are obvious pre-requisites to their further epidemiological characterization or research into their resistance and virulence characteristics. Complete diagnostic data sets can then be used for curing patients or for prevention of cross infection and infection control.

In the current era of multi-to-pan antibiotic resistance, there is an increasing interest in microbial tests that detect antibiotic resistance, one of the current medical scourges (Okeke et al., 2011; Kelly et al., 2016). Although phenotypic analysis is our heritage, optimal molecular diagnosis should allow for the simultaneous detection, identification, and genetic antibiotic susceptibility testing (AST) of infectious agents. DNA sequences at the species level and at the level of resistance genes can be amplified at the same time in the same assay using the same clinical material as source (see Figure 1 for a conceptual explanation). Indirect AST results in the detection of resistance markers and should lead to targeted treatment on the basis of the presumed activity of the product for which only the gene was detected. When innovative analytical techniques such as mass spectrometry, liquid chromatography, and nucleic acid sequencing are included advices on treatment may become more encompassing and cover-all.

FIGURE 1 Comparison between direct AST and indirect AST, showing the difference between the laboratory based and PoC protocols. Whereas the laboratory exercise generates precise minimum inhibitory concentrations (MICs), the indirect approach generates markers that need to be associated with therapeutic modalities through bio-informatics.

Here, we will focus on the detection of meticillin resistance in the bacterial species Staphylococcus aureus as a model for the recent evolution of and the huge value of AST in clinical care. Meticillin-resistant S. aureus (MRSA) generates twice as much mortality than methicillin-susceptible S. aureus (MSSA) (Turnidge et al., 2009) and rapid molecular diagnostics has already been shown to reduce hospital stay and costs associated with MRSA infection (Brown and Paladino, 2010). Detecting both MSSA and MRSA is important since it guides therapeutic interventions with optimal antibiotics (Liu et al., 2011). Successful molecular diagnostic tests were developed by individual researchers (in house technology) but also by the IVD industry. In addition, quantification of the absolute number of bacterial cells in a clinical specimen is also important since different bacterial titers may be involved in colonization versus infection of human individuals. We review nucleic acid-based tests that have been made recently available for the detection of MSSA and MRSA. When such tests are correctly used they do facilitate subsequent studies into the epidemiology, evolution, and spread of both MSSA and MRSA. Detailed assessment of resistance to a wider spectrum of antimicrobial agents can be performed and implementation of enhanced infection control becomes an option.

Culture-Based Detection of MSSA and MRSA
There is no way of discussing molecular detection of MSSA and MRSA without briefly sketching the pre- and peri-molecular diagnostic landscape. Traditionally, staphylococcal colonization, and infection were diagnosed using culture-based technologies. These either employ generic, highly fertile culture media coupled to downstream bacterial species identification or species-specific enrichment media containing S. aureus selective components such as elevated salt concentrations. Addition of chromogenic compounds in the medium helps to identify S. aureus on the basis of colony morphology and color (Perry, 2017). Further taxonomic classification and identification of S. aureus can be done via agglutination assays or (commercially available) biochemical reactivity (e.g., API strips). Using combinations of simple phenotypic tests has been shown to allow for the adequate distinction of MSSA and MRSA (Verroken et al., 2016; Lüthje et al., 2017; Rees and Barr, 2017; Ábrók et al., 2018). Recent immunochromatographic methods such as the BinaxNOW (Alere, Scarborough, ME, United States) and the Clearview Exact PBP2a assay (Alere, Scarborough, ME, United States) have acquired a good position in the clinical laboratory given their modest price, rapidity, and good sensitivity and specificity (e.g., Kong et al., 2014). Still, modern laboratories now consider matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI ToF MS) as Gold Standard for staphylococcal identification (Bernardo et al., 2002; Szabados et al., 2010; Zhu et al., 2015). Distinguishing MRSA from MSSA using MALDI ToF MS is controversial with positive reports (Ueda et al., 2015; Rhoads et al., 2016; Sogawa et al., 2017) alternating with more negative ones (Du et al., 2002; Goldstein et al., 2013). Recent papers document the successful distinction between MSSA and MRSA, even including characterization of different MRSA clones (Østergaard et al., 2015; Zhang et al., 2015; Camoez et al., 2016). The main issue with these studies is that MALDI TOF MS detects proteins and that it is claimed that the mecA protein is produced in small amounts, often impossible to detect even by targeted mass spectrometry methods. So there is a significant risk that MALDI TOF MS will detect surrogate markers that also distinguish MRSA from MSSA. These may be markers of clonality rather than methicillin resistance and for this reason the collection of (preferably epidemiologically non-related) strains is of key importance. However, the overall impression is that MALDI ToF MS can be useful in the field of bacterial epidemiology but it will certainly not provide a universal "typing" solution. Advanced MS methods, including for instance electron spray ionization (ESI) MS, may bring more universal solutions but these methods are too cumbersome, too time-consuming and too expensive at this stage (Charretier et al., 2015). Although MS essentially provides molecular testing, albeit at the protein level, NAATs still provide the best tool for distinguishing MSSA and MRSA.

Short Introduction into Molecular Technologies
Using polymerase chain reaction (PCR), nucleic acid sequence-based amplification (NASBA), recombinase polymerase amplification (RPA), loop-mediated isothermal amplification (LAMP) and other systems, minute amounts of DNA can be amplified and detected using a variety of technological formats (Almassian et al., 2013; Yan et al., 2014). All of these methods have been shown to be useful in the detection of infectious agents and both PCR and several non-PCR tests have been commercialized (e.g., the LAMP-based Eazyplex test, see Henares et al., 2017). New methods surface regularly (e.g., those methods employing the specificity, sensitivity of enzymes involved in CRISPCas-mediated bacterial immunity to bacteriophages, see Gootenberg et al., 2017, 2018, for more details), several of them allowing genetic AST, and this import of new testing formats including their automatization will continue in the years to come.

There is a set of technologies that will undoubtedly have a huge impact on microbial detection and characterization: next generation sequencing (NGS) leading to the elucidation of the primary structure of complete bacterial chromosome sequences. Multiple elegant whole genome sequencing (WGS) NGS technologies have been developed three of which are currently commercialized and well-accessible to the diagnostic laboratory. Companies such as Illumina (San Diego, CA, United States), PacBio (Menlo Park, CA, United States), and Oxford Nanopore (Oxford, United Kingdom) provide exemplary methodologies suited for WGS. Further technical and usage detail on these methods will not be provided here but can be easily accessed through various recent reviews (Miyamoto et al., 2014; Quainoo et al., 2017; Rossen et al., 2017). NGS will find its way into the clinical microbiology routine laboratory over the years to come where it will fill in important niches in the rapid detection of pathogens and their epidemiological, antibiotic resistance, and virulence characteristics, possibly directly from clinical specimens. NGS will allow parallel sequencing of host DNA and define the host's susceptibility to certain diseases. High throughput sequencing of RNA will allow for more precise expression monitoring via transcriptomics.

Realistically speaking though, we currently dispose of two main techniques for distinction between MSSA and MRSA: those targeting specific diagnostic signature sequences and those that characterize entire chromosomes and then depend on bio-informatic analyses to highlight the presence of the same sequence motifs used by the specific methods (Figure 1).

Targeted Genetic Detection of MSSA and MRSA
It needs to be realized that for the molecular detection of MRSA there should be a differentiation between screening tests (for carriage) and hard-core diagnostic tests for infection (Osiecki, 2010; Trouillet-Assant et al., 2013). Both tests have different requirements for sensitivity, specificity, costs, and speed. Screening may not need high-speed but must be focused on specific detection of high-rate carriers (Bode et al., 2010). A major hurdle to developing molecular MRSA-specific tests is the fact that the gene encoding meticillin resistance occurs in other staphylococcal species as well. A solution to this issue is the inclusion of species-specific assays in the amplification reaction (e.g., targeting the nuc or femA genes). The second hurdle is that the mec gene is present in four variants (mecA, mecC, and the more recently discovered mecB (Gómez-Sanz et al., 2015; Becker et al., 2018) and mecD (Schwendener et al., 2017)) and these reside in a growing number of genetic islands (Kolenda et al., 2017); mec genes are embedded in various Staphylococcal Cassette Chromosome mec (SCCmec) for which more than 10 different types have already been identified (Hill-Cawthorne et al., 2014; Kaya et al., 2018). Molecular tests for rapid discrimination of SCCmec types continue to be developed though their use is mostly of epidemiological rather than clinical value (Brukner et al., 2013). The mecC variant, mostly found in livestock associated MRSA and sharing about 70% sequence homology with mecA, was discovered as recently as 2011 (García-Álvarez et al., 2011). Finally, rapidity of a test can be affected by whether or not a test is (semi-)quantitative and performed in real-time or not (Verhoeven et al., 2012). The need for real-time testing differs per clinical application but in case of sepsis detection, for instance, speed is of utmost importance (Frye et al., 2012). Modern MRSA detection obviously is part of multiplexed, syndrome-oriented diagnostic testing (Blaschke et al., 2012; Ramanan et al., 2017).

A variety of experimental testing formats has been suggested for targeted MRSA detection but most of which have not reached the diagnostic market (yet). Table 1 reviews the status of a significant number of current PCR tests and highlights a domain of importance: the next generation routine-applicable tests may very well-originate from this pool of potentially high throughput tools.

Table 1 Global review of future and commercial PCR tests for meticillin-resistant and -susceptible strains of Staphylococcus aureus.

Company	Status	Concise product description	Duration of test	
Abacus Diagnostica, Finland	In development	Rapid DNA testing with proprietary GenomEra CDX-technology for identification of MRSA	50 min	
AdvanDx, United States	FDA approved	Staphylococcus QuickFISH filter in situ hybridization test for positive blood culture liquid	20 min	
Akonni Biosystems, United States	In development	TruArray MRSA, qualitative test for detection of SA and MRSA	Non-specified	
Atlas Genetics, United Kingdom	In development	Mixed technology linking NAT and immunology for MRSA, Dual MRSA/MSSA	0.5 h	
Autoi/mmun Diagnostika, Germany	CE certified	Automated AID Scanner, line probe Western blot probe assay after PCR amplification, 100 strips per hour	4 h	
Biocartis, Belgium	In development	Idylla platform for multiplex real-time PCR assay for rapid detection of bloodstream infections	2 h	
BioFire, United States	FDA approved, new tests in development	FDA approved syndromic panels for respiratory, gastro-intestinal, and meningitis/encephalitis associated pathogens; the BCID test also covers mecA. Sample in—result out strategy	1 h	
BD, United States	FDA approved, new tests in development	Platform BD Max. MRSA + MSSA + mecA test	<3 h	
Cepheid, United States (acquired by Danaher)	FDA approved for HAI with MRSA/SA	Validated for positive blood culture. Xpert test format. MRSA, SA Nasal Complete, MRSA/SA SSTI, MRSA/SA BC	2 h	
Coyote Biosci, United States, China	In development	Platform Mini 8 RT PCR; throat swab/Blood sample—MRSA	10–30 min	
Curetis AG, Germany	CE marked, precise status not very clear	Platform Univero; >100 pathogens and resistance genes, P55 Application focuses on pneumonia, 21 pathogens, and 19 resistance markers, 40-plex. i60 ITI Application Cartridge (23 organisms and 19 resistance genes)	4–5 h	
DXna, United States	CE marked	GeneSTAT portable RT PCR platform, MRSA/MRCoNS in development for 2017	1 h	
Epoch Biosciences, Elitech Group	FDA approved	Triplex Real Time Amplification tests using minor groove binding DNA probes	1 h	
Genesig	RUO	Quantitative PCR for various targets among which MRSA; 16 samples per run	90–120 min	
GenMark, United States	In development	Platform ePlex. Electronic sensor technology, DNA hybridization, and electrochemical detection	4 h	
Genspeed, Austria	In development	Straightforward PCR with hybridization confirmation, combination of microfluidics, miniaturized opto-electronics, and automation	100 min	
GFC Diagnostics	In development	Microscreen enzymatic-colorigenic DNA hybridization test on Safetube device	Non-specified	
Great Basin Scientific, United States	Early stage	Whole blood, multiplexed nucleic-acid based assay using an opto-fluidic device; announced for 2021	Non-specified	
Grenier Bio-One, United States	CE marked, not FDA cleared	PCR-based chip-probe Genspeed platform. Genspeed MRSA distinguishes MRSA/MRSE or mecA/C positive S. haemolyticus	1.5 h	
Hain, Germany	CE marked for many tests	PCR/hybridization platform. GenoType, FluoroType and GenoQuick technologies, MRSA, CoNS	2.5 h	
Icubate, United States	RUO	Random access multiplex PCR disposable test cassette for pathogens and resistances. Portfolio: gram + MSSA, S. epidermidis, MRSA	Non-specified	
ID Biomedical, Corp., Vancouver	Early stage	Velogene rapid MRSA identification assay	2 h	
Linear Diagnostics, Ltd.	In development	Detection of aligned substrate or PCR fragment via polarized light	Non-specified	
Magnomics, Portugal	In development	Chip DNA extraction, amplification, and magnetic detection. Primary for veterinary application	1 h	
Mobidiag, Finland	CE marked	Novodiag and Amplidiag product line. Sepsis, 60 bacterial species, 13 fungi, and mecA in one assay	3.5 h	
Nanosphere Inc, United States	FDA cleared	DNA amplification-hybridization. Verigene BC-GP and BC-GN. Gold Nanoparticle Technology with oligo-hybridization to target DNA, narrow temperature range	2–2.5 h	
Opgen, United States	Not clear	Real-time C. difficile and MRSA DNA testing. The Acuitas CRE Elite MDRO Gene Test detects 10 genes unique to MDRO from swabs to colonies	Non-specified	
Pathogenica, Japan	RUO	Pathogenica's DxSeq is a sequencing product. The HAI BioDetection Kit assays over 12 pathogens and 15 resistance gene families	Non-specified	
Roche Molecular Systems, Germany	FDA approved	COBAS 4800 and the Liat MRSA/MSSA PCR tests	1 h	
Tests and companies may be missing and for several tests there are no peer-reviewed performance data. Diasorin and Luminex announced assays last year but the descriptions are not very precise. Same for the Spanish company Stat DX, which was recently acquired by Qiagen. Bruker and Siemens are said to be working on high throughput systems. Visibility of Chinese and Indian competitors in this field is also limited. Any mistakes are the authors' responsibility.(BC)ID, (blood culture) identification; CE, Certification Europeènne; CoNS, coagulase negative staphylococci; FDA, Food and Drug Administration; GP/N, gram positive/negative; HAI, hospital acquired infection; MDRO, multi-drug resistant organism; (MR)SA, (methicillin-resistant) S. aureus; SSTI, skin and soft tissue infection.Some of the technologies are worth mentioning separately given the fact that they can be considered extremely elegant from an experimental design point of view. Digital droplet PCR for instance was shown to be sensitive and rapid and it has to be realized that instruments allowing in house development of droplet-based PCR tests are already (commercially) available (Luo et al., 2017). Nanowires are attractive because of size, relatively low costs, and speed of the assay and broad applicability of the technology which, in addition, is easy to multiplex (Ibarlucea et al., 2017). Similarly, using albumin stabilized fluorescent gold nanoclusters as selective probes, MSSA and MRSA can be reliably distinguished (Chan and Chen, 2012). Sensitivity and specificity of these often still quite experimental tests are usually good and offer a positive perspective on future developments in this field (Bakthavatchalam et al., 2017). Note that Table 1 highlights the post-PCR use of array technology, filter in situ hybridization, minor groove binding DNA probes, and magnetic capturing as additional clever read-out methods.

Laboratory-Based vs. PoC Testing
Classical testing for microbial pathogens usually leads to amplification of viable cells. This requires the use of specialized laboratories where employees and the community outside of the lab are protected from infection through specific control measures. This has often blocked PoC test development and deployment. Now, with the possibility to detect pathogens by amplifying non-infectious components of such pathogens the door toward out-of-laboratory testing has been opened wide. Miniaturized tools have been developed that are based on microfluidics (Yeh et al., 2017), LAMP combined with cellulose-based nucleic acid binding paper (Bearinger et al., 2011), isothermal amplification tests (Toley et al., 2015) but also based upon labeling- and amplification-free techniques (Corrigan et al., 2013). With such technologies in mind it was established that PoC testing for MSSA and MRSA was among the priorities when remote and even disaster testing was due (Brock et al., 2010; Kost et al., 2012). Clearly, tools for bedside diagnostics are available that allow for in-department infection control and outbreak management.

In PoC testing both technical and clinical aspects are of key importance. Technical requirements are largely covered by the WHO ASSURED criteria. The acronym lists affordability, sensitivity, specificity, user-friendliness, rapidity and robustness, no need for complicated equipment, and providing solutions that can be easily delivered to end users. If all these requirement are met in a single test (which at this stage is non-existent) then clinical applicability is essentially global. However, if a test would, for example, be too expensive then application in developing economies would essentially be blocked. MRSA/MSSA PoC tests would be particularly useful for rapid assessment of (nasal) carriage for infection control, whereas screening for staphylococcal wound infection and respiratory infection would also have strong added value.

The first PoC MRSA projects have been published. Leone et al. (2013) did an intensive care-based study into the use of MSSA/MRSA detection in patients with ventilator-associated pneumonia. They showed that with a negative predictive value of 99.8% PoC testing efficiently excluded the presence of MRSA among the patients. They did warn that the reliability of this type of testing is dependent on the local prevalence of MRSA carriage. In an orthopedic readmission study it was shown that the Cepheid Xpert MRSA with its 75% sensitivity in this groups of patients with complicated problems performed quite well (Parcell and Phillips, 2014). Screening more than 10,000 patients at admission for detection of MRSA carriage was very efficient as well (Wu et al., 2017). Although the list of publications is relatively short, it is clear that detection of MSSA/MRSA at the PoC fulfills a real medical need. In case of epidemic spread of MRSA clones rapid and sensitive detection are key and in many cases the use of PoC testing allows for accelerated testing in comparison with more conventional laboratory assays. Speed really is the key to high throughput surveillance and subsequent rapid infection control.

Genomic Detection of MSSA and MRSA
Single genomic molecules can be captured to microscopic beads, which are equipped with biotinylated probes to which streptavidin-complexed galactosidase binds and which facilitates the detection of sub-femtomolar concentrations of specific DNA molecules. This Single Molecule Array tests (developed by Quanterix Corporation, Lexington, MA, United States) has been adapted for the detection of MRSA as well (Song et al., 2013). Beyond capturing and detecting "full" genomes, there is now also the option to have a staphylococcal genome sequenced de novo and in toto. Thousands of MSSA and MRSA strains have been subjected to genome sequencing and the software that allows for post-sequencing detection of the mec genes is available (Gordon et al., 2014). Current and well-known software packages for such purposes include CLC Bio (Qiagen, Hilden, Germany), Seqsphere (Ridom, Münster, Germany), and Bionumerics (Applied Maths, bioMérieux, St. Martens Lathem, Belgium). Hence genomic characterization of MRSA is feasible and with the rise in sequencing directly from clinical specimens the impact of direct detection of MRSA will change significantly over the years to come (Lefterova et al., 2015). However, in order to be applicable in routine high-throughput clinical laboratories the technology needs to be quicker, less expensive with data that should be easy to interpret preferably in a (semi-)quantitative fashion. Obviously, genome sequencing provides the ultimate tool for epidemiological typing of MRSA and MSSA (Quainoo et al., 2017) and many studies where NGS has been exploited to define epidemiological patterns of spreading of MRSA have been published before (Tewhey et al., 2012; Price et al., 2013; Stone et al., 2013; Kong et al., 2016; Ward et al., 2016; Planet et al., 2017; and references therein).

Concluding Remarks
Whereas classical detection and speciation of staphylococci has improved significantly upon the introduction of MALDI ToF MS in the diagnostic laboratory, molecular tests, mostly based on specific gene amplification, are still required for the rapid distinction between MSSA and MRSA. The availability of WGS and NGS has now opened up alternative avenues for the detection of resistance genes, the mec-variants included. The near future will bring (genome) sequencing and comprehensive software packages allowing for the unequivocal bio-informatic AST of MSSA and MRSA using WGS, even for non-bio-informaticians. The position of PoC testing in all of this is still poorly defined and needs to be clarified. Inclusion of additional patient data beyond laboratory results is an important additive to the optimization of PoC testing (Yoshioka et al., 2018). In conclusion, molecular testing for MRSA has been accepted by the diagnostic community and is performing well. New technology will challenge the molecular tests and there will be fierce clinical, commercial, and academic completion before full acceptation of the new wave of genomic testing formats.

Author Contributions
AB and OR: conceived, wrote and illustrated the manuscript. Data for the table was assembled using aimed searches in relevant databases and publicly available information in a variety of corporate websites and communications between company employees and the authors. Omissions in the table are for the responsibility of the authors only.

Conflict of Interest Statement
The authors are employees of bioMérieux, a company designing, developing, and selling diagnostic assays in the field of infectious diseases. Opinions and conclusions phrased in the current text are the author's, not necessarily equaling the formal bioMérieux policies.

Funding. Research in the laboratory of AB has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie (Grant Agreement No. 675412) [New Diagnostics for Infectious Diseases (ND4ID)].
==== Refs
References
Ábrók M. Lázár A. Szécsényi M. Deák J. Urbán E.   (2018 ). Combination of MALDI-TOF MS and PBP2' latex agglutination assay for rapid MRSA detection. 
J. Microbiol. Methods 
144 
122 –124 . 10.1016/j.mimet.2017.11.021 
29180272 
Almassian D. R. Cockrell L. M. Nelson W. M.   (2013 ). Portable nucleic acid thermocyclers. 
Chem. Soc. Rev. 
42 
8769 –8798 . 10.1039/c3cs60144g 
24030680 
Bakthavatchalam Y. D. Nabarro L. E. Veeraraghavan B.   (2017 ). Evolving rapid methicillin-resistant Staphylococcus aureus detection: cover all the bases. 
J. Glob. Infect. Dis. 
9 
18 –22 . 10.4103/0974-777X.199997 
28250621 
Bearinger J. P. Dugan L. C. Baker B. R. Hall S. B. Ebert K. Mioulet V.   (2011 ). Development and initial results of a low cost, disposable, point-of-care testing device for pathogen detection. 
IEEE Trans. Biomed. Eng. 
58 
805 –808 . 10.1109/TBME.2010.2089054 
21342806 
Becker K. van Alen S. Idelevich E. A. Schleimer N. Seggewiß J. Mellmann A.   (2018 ). Plasmid-encoded transferable mecB-mediated methicillin resistance in Staphylococcus aureus. 
Emerg. Infect. Dis. 
24 
242 –248 . 10.3201/eid2402.171074 
29350135 
Bernardo K. Pakulat N. Macht M. Krut O. Seifert H. Fleer S.   (2002 ). Identification and discrimination of Staphylococcus aureus strains using matrix-assisted laser desorption/ionization-time of flight mass spectrometry. 
Proteomics 
2 
747 –753 . 10.1002/1615-9861(200206)2:6<8b7c:f320:99b9:690f:4595:cd17:293a:c069AID-PROT747>3.0.CO;2-V 
12112858 
Blaschke A. J. Heyrend C. Byington C. L. Fisher M. A. Barker E. Garrone N. F.   (2012 ). Rapid identification of pathogens from positive blood cultures by multiplex polymerase chain reaction using the FilmArray system. 
Diagn. Microbiol. Infect. Dis. 
74 
349 –355 . 10.1016/j.diagmicrobio.2012.08.013 
22999332 
Bode L. G. Kluytmans J. A. Wertheim H. F. Bogaers D. Vandenbroucke-Grauls C. M. Roosendaal R.   (2010 ). Preventing surgical-site infections in nasal carriers of Staphylococcus aureus. 
N. Engl. J. Med. 
362 
9 –17 . 10.1056/NEJMoa0808939 
20054045 
Brock T. K. Mecozzi D. M. Sumner S. Kost G. J.   (2010 ). Evidence-based point-of-care tests and device designs for disaster preparedness. 
Am. J. Disaster Med. 
5 
285 –294 . 21162410 
Brown J. Paladino J. A.   (2010 ). Impact of rapid methicillin-resistant Staphylococcus aureus polymerase chain reaction testing on mortality and cost effectiveness in hospitalized patients with bacteraemia: a decision model. 
Pharmacoeconomics 
28 
567 –575 . 10.2165/11533020-000000000-00000 
20550222 
Brukner I. Oughton M. Giannakakis A. Kerzner R. Dascal A.   (2013 ). Significantly improved performance of a multitarget assay over a commercial SCCmec-based assay for methicillin-resistant Staphylococcus aureus screening: applicability for clinical laboratories. 
J. Mol. Diagn. 
15 
577 –580 . 10.1016/j.jmoldx.2013.04.009 
23867076 
Camoez M. Sierra J. M. Dominguez M. A. Ferrer-Navarro M. Vila J. Roca I.   (2016 ). Automated categorization of methicillin-resistant Staphylococcus aureus clinical isolates into different clonal complexes by MALDI-TOF mass spectrometry. 
Clin. Microbiol. Infect. 
22  .e1 –.e161 . 10.1016/j.cmi.2015.10.009 
26363405 
Chan P. H. Chen Y. C.   (2012 ). Human serum albumin stabilized gold nanoclusters as selective luminescent probes for Staphylococcus aureus and methicillin-resistant Staphylococcus aureus. 
Anal. Chem. 
84 
8952 –8956 . 10.1021/ac302417k 
23088348 
Charretier Y. Dauwalder O. Franceschi C. Degout-Charmette E. Zambardi G. Cecchini T.   (2015 ). Rapid bacterial identification, resistance, virulence and type profiling using selected reaction monitoring mass spectrometry. 
Sci. Rep. 
5 :13944 . 10.1038/srep13944 
26350205 
Corrigan D. K. Schulze H. Henihan G. Hardie A. Ciani I. Giraud G.   (2013 ). Development of a PCR-free electrochemical point of care test for clinical detection of methicillin resistant Staphylococcus aureus (MRSA). 
Analyst 
138 
6997 –7005 . 10.1039/c3an01319g 
24093127 
Du Z. Yang R. Guo Z. Song Y. Wang J.   (2002 ). Identification of Staphylococcus aureus and determination of its methicillin resistance by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. 
Anal. Chem. 
74 
5487 –5491 . 10.1021/ac020109k 
12433077 
Frye A. M. Baker C. A. Rustvold D. L. Heath K. A. Hunt J. Leggett J. E.   (2012 ). Clinical impact of a real-time PCR assay for rapid identification of staphylococcal bacteremia. 
J. Clin. Microbiol. 
50 
127 –133 . 10.1128/JCM.06169-11 
22075595 
García-Álvarez L. Holden M. T. Lindsay H. Webb C. R. Brown D. F. Curran M. D.   (2011 ). Meticillin-resistant Staphylococcus aureus with a novel mecA homologue in human and bovine populations in the UK and Denmark: a descriptive study. 
Lancet Infect. Dis. 
11 
595 –603 . 10.1016/S1473-3099(11)70126-8 
21641281 
Goldstein J. E. Zhang L. Borror C. M. Rago J. V. Sandrin T. R.   (2013 ). Culture conditions and sample preparation methods affect spectrum quality and reproducibility during profiling of Staphylococcus aureus with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. 
Lett. Appl. Microbiol. 
57 
144 –150 . 10.1111/lam.12092 
23617594 
Gómez-Sanz E. Schwendener S. Thomann A. Gobeli Brawand S. Perreten V.   (2015 ). First Staphylococcal cassette chromosome mec containing a mecB-carrying gene complex independent of transposon Tn6045 in a Macrococcus caseolyticus isolate from a canine infection. 
Antimicrob. Agents Chemother. 
59 
4577 –(847)457-3314/AAC.05064-14 
25987634 
Gootenberg J. S. Abudayyeh O. O. Kellner M. J. Joung J. Collins J. J. Zhang F.   (2018 ). Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. 
Science 
360 
439 –444 . 10.1126/science.aaq0179 
29449508 
Gootenberg J. S. Abudayyeh O. O. Lee J. W. Essletzbichler P. Dy A. J. Joung J.   (2017 ). Nucleic acid detection with CRISPR-Cas13a/C2c2. 
Science 
356 
438 –442 . 10.1126/science.aam9321 
28408723 
Gordon N. C. Price J. R. Cole K. Everitt R. Morgan M. Finney J.   (2014 ). Prediction of Staphylococcus aureus antimicrobial resistance by whole-genome sequencing. 
J. Clin. Microbiol. 
52 
1182 –1191 . 10.1128/JCM.03117-13 
24501024 
Henares D. Brotons P. Buyse X. Latorre I. de Paz H. D. Muñoz-Almagro C.   (2017 ). Evaluation of the eazyplex MRSA assay for the rapid detection of Staphylococcus aureus in pleural and synovial fluid. 
Int. J. Infect. Dis. 
59 
(847)457-3314/j.ijid.2017.04.013 
28450195 
Hill-Cawthorne G. A. Hudson L. O. El Ghany M. F. Piepenburg O. Nair M. Dodgson A.   (2014 ). Recombinations in staphylococcal cassette chromosome mec elements compromise the molecular detection of methicillin resistance in Staphylococcus aureus. 
PLoS One 
9 :e101419 . 10.1371/journal.pone.0101419 
24972080 
Ibarlucea B. Rim T. Baek C. K. de Visser J. A. G. M. Baraban L. Cuniberti G.   (2017 ). Nanowire sensors monitor bacterial growth kinetics and response to antibiotics. 
Lab Chip 
17 
4283 –4293 . 10.1039/c7lc00807d 
29119168 
Kaya H. Hasman H. Larsen J. Stegger M. Johannesen T. B. Allesøe R. L.   (2018 ). SCCmecFinder, a web-based tool for typing of Staphylococcal cassette chromosome mec in Staphylococcus aureus using whole-genome sequence data. 
mSphere 
3 :e00612 -17. 10.1128/mSphere.00612-17 
29468193 
Kelly R. Zoubiane G. Walsh D. Ward R. Goossens H.   (2016 ). Public funding for research on antibacterial resistance in the JPIAMR countries, the European Commission, and related European Union agencies: a systematic observational analysis. 
Lancet Infect. Dis. 
16 
431 –440 . 10.1016/S1473-3099(15)00350-3 
26708524 
Kolenda C. Dupieux C. Decousser J. W. Larsen A. R. Pichon B. Holmes M.   (2017 ). Comparison of automated antimicrobial susceptibility testing systems to detect mecC-positive methicillin-resistant Staphylococcus aureus. 
J. Clin. Microbiol. 
55 
3554 –3556 . 10.1128/JCM.01150-17 
28904189 
Kong H. Tong L. Zhang W. Fu Y. Li X.   (2014 ). Combined use of the BinaxNOW Staphylococcus aureus test with the Clearview PBP2a assay for the early detection of methicillin-resistant S. aureus from positive blood cultures. 
Diagn. Microbiol. Infect. Dis. 
78 
226 –228 . 10.1016/j.diagmicrobio.2013.11.018 
24360266 
Kong Z. Zhao P. Liu H. Yu X. Qin Y. Su Z.   (2016 ). Whole-genome sequencing for the investigation of a hospital outbreak of MRSA in China. 
PLoS One 
11 :e0149844 . 10.1371/journal.pone.0149844 
26950298 
Kost G. J. Mecozzi D. M. Brock T. K. Curtis C. M.   (2012 ). Assessing point-of-care device specifications and needs for pathogen detection in emergencies and disasters. 
Point Care 
11 
(847)457-3314/POC.0b013e31825a25cb 
23049471 
Lefterova M. I. Suarez C. J. Banaei N. Pinsky B. A.   (2015 ). Next-generation sequencing for infectious disease diagnosis and management: a report of the association for molecular pathology. 
J. Mol. Diagn. 
17 
623 –634 . 10.1016/j.jmoldx.2015.07.004 
26433313 
Leone M. Malavieille F. Papazian L. Meyssignac B. Cassir N. Textoris J.   (2013 ). Routine use of Staphylococcus aureus rapid diagnostic test in patients with suspected ventilator-associated pneumonia. 
Crit. Care 
17 :R170 . 10.1186/cc12849 
23919575 
Liu C. Bayer A. Cosgrove S. E. Daum R. S. Fridkin S. K. Gorwitz R. J.   (2011 ). Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. 
Clin. Infect. Dis. 
52 
e18 –e55 . 10.1093/cid/ciq146 
21208910 
Luo J. Li J. Yang H. Yu J. Wei H.   (2017 ). Accurate detection of methicillin-resistant Staphylococcus aureus in mixtures by use of single-bacterium duplex droplet digital PCR. 
J. Clin. Microbiol. 
55 
2946 –2955 . 10.1128/JCM.00716-17 
28724560 
Lüthje P. Pranada A. B. Carruthers-Lay D. Desjardins M. Gaillot O. Wareham D.   (2017 ). Identification of microorganisms grown on chromogenic media by MALDI-TOF MS. 
J. Microbiol. Methods 
136 
17 –20 . 10.1016/j.mimet.2017.03.001 
28267570 
Miyamoto M. Motooka D. Gotoh K. Imai T. Yoshitake K. Goto N.   (2014 ). Performance comparison of second- and third-generation sequencers using a bacterial genome with two chromosomes. 
BMC Genomics 
15 :699 . 10.1186/1471-2164-15-699 
25142801 
Muldrew K. L.   (2009 ). Molecular diagnostics of infectious diseases. 
Curr. Opin. Pediatr. 
21 
102 –111 . 10.1097/MOP.0b013e328320d87e 
19242246 
Okeke I. N. Peeling R. W. Goossens H. Auckenthaler R. Olmsted S. S. de Lavison J. F.   (2011 ). Diagnostics as essential tools for containing antibacterial resistance. 
Drug Resist. Updat. 
14 
95 –106 . 10.1016/j.drup.2011.02.002 
21398170 
Osiecki J.   (2010 ). MRSA Screening: Culture or Molecular?  Available at: www.advanceweb.com
Østergaard C. Hansen S. G. Møller J. K.   (2015 ). Rapid first-line discrimination of methicillin resistant Staphylococcus aureus strains using MALDI-TOF MS. 
Int. J. Med. Microbiol. 
305 
838 –847 . 10.1016/j.ijmm.2015.08.002 
26365166 
Parcell B. J. Phillips G.   (2014 ). Use of Xpert MRSA PCR point-of-care testing beyond the laboratory. 
J. Hosp. Infect. 
87 
119 –121 . 10.1016/j.jhin.2014.04.002 
24836293 
Perry J. D.   (2017 ). A decade of development of chromogenic culture media for clinical microbiology in an era of molecular diagnostics. 
Clin. Microbiol. Rev. 
30 
449 –479 . 10.1128/CMR.00097-16 
28122803 
Planet P. J. Narechania A. Chen L. Mathema B. Boundy S. Archer G.   (2017 ). Architecture of a species: phylogenomics of Staphylococcus aureus. 
Trends Microbiol. 
25 
153 –166 . 10.1016/j.tim.2016.09.009 
27751626 
Price J. Gordon N. C. Crook D. Llewelyn M. Paul J.   (2013 ). The usefulness of whole genome sequencing in the management of Staphylococcus aureus infections. 
Clin. Microbiol. Infect. 
19 
784 –789 . 10.1111/1469-0691.12109 
23331482 
Quainoo S. Coolen J. P. M. van Hijum S. A. F. T. Huynen M. A. Melchers W. J. G. van Schaik W.   (2017 ). Whole-genome sequencing of bacterial pathogens: the future of nosocomial outbreak analysis. 
Clin. Microbiol. Rev. 
30 
1015 –1063 . 10.1128/CMR.00016-17 
28855266 
Ramanan P. Bryson A. L. Binnicker M. J. Pritt B. S. Patel R.   (2017 ). Syndromic panel-based testing in clinical microbiology. 
Clin. Microbiol. Rev. 
31 :e00024 -17. 10.1128/CMR.00024-17 
29142077 
Rees J. C. Barr J. R.   (2017 ). Detection of methicillin-resistant Staphylococcus aureus using phage amplification combined with matrix-assisted laser desorption/ionization mass spectrometry. 
Anal. Bioanal. Chem. 
409 
1379 –1386 . 10.1007/s00216-016-0070-3 
27866257 
Rhoads D. D. Wang H. Karichu J. Richter S. S.   (2016 ). The presence of a single MALDI-TOF mass spectral peak predicts methicillin resistance in staphylococci. 
Diagn. Microbiol. Infect. Dis. 
86 
257 –261 . 10.1016/j.diagmicrobio.2016.08.001 
27568365 
Rossen J. W. A. Friedrich A. W. Moran-Gilad J.  
ESCMID study group for genomic and molecular diagnostics (ESGMD)  (2017 ). Practical issues in implementing whole-genome-sequencing in routine diagnostic microbiology. 
Clin. Microbiol. Infect. 
24 
355 –360 . 10.1016/j.cmi.2017.11.001 
29117578 
Schwendener S. Cotting K. Perreten V.   (2017 ). Novel methicillin resistance gene mecD in clinical Macrococcus caseolyticus strains from bovine and canine sources. 
Sci. Rep. 
7 :43797 . 10.1038/srep43797 
28272476 
Sogawa K. Watanabe M. Ishige T. Segawa S. Miyabe A. Murata S.   (2017 ). Rapid discrimination between methicillin-sensitive and methicillin-resistant Staphylococcus aureus using MALDI-TOF mass spectrometry. 
Biocontrol Sci. 
22 
163 –169 . 10.4265/bio.22.163 
28954959 
Song L. Shan D. Zhao M. Pink B. A. Minnehan K. A. York L.   (2013 ). Direct detection of bacterial genomic DNA at sub-femtomolar concentrations using single molecule arrays. 
Anal. Chem. 
85 
1932 –1939 . 10.1021/ac303426b 
23331316 
Stone M. J. Wain J. Ivens A. Feltwell T. Kearns A. M. Bamford K. B.   (2013 ). Harnessing the genome: development of a hierarchical typing scheme for meticillin-resistant Staphylococcus aureus. 
J. Med. Microbiol. 
62 (Pt 1) , (847)457-3314/jmm.0.049957-0 
23002072 
Suh H. J. Park W. B. Jung S.-I. Song K.-H. Kwak Y. G. Kim K.-H.   (2018 ). A risk scoring system for predicting methicillin resistance in community-onset Staphylococcus aureus bacteremia in Korea. 
Microb. Drug Resist. 
24 
556 –562 . 10.1089/mdr.2017.0236 
29863981 
Szabados F. Woloszyn J. Richter C. Kaase M. Gatermann S.   (2010 ). Identification of molecularly defined Staphylococcus aureus strains using matrix-assisted laser desorption/ionization time of flight mass spectrometry and the Biotyper 2.0 database. 
J. Med. Microbiol. 
59 (Pt 7) , 787 –790 . 10.1099/jmm.0.016733-0 
20360398 
Tewhey R. Cannavino C. R. Leake J. A. Bansal V. Topol E. J. Torkamani A.   (2012 ). Genetic structure of community acquired methicillin-resistant Staphylococcus aureus USA300. 
BMC Genomics 
13 :508 . 10.1186/1471-2164-13-508 
23009684 
Toley B. J. Covelli I. Belousov Y. Ramachandran S. Kline E. Scarr N.   (2015 ). Isothermal strand displacement amplification (iSDA): a rapid and sensitive method of nucleic acid amplification for point-of-care diagnosis. 
Analyst 
140 
7540 –(847)457-3314/c5an01632k 
26393240 
Trouillet-Assant S. Rasigade J. P. Lustig S. Lhoste Y. Valour F. Guerin C.   (2013 ). Ward-specific rates of nasal cocolonization with methicillin-susceptible and -resistant Staphylococcus spp. and potential impact on molecular methicillin-resistant Staphylococcus aureus screening tests. 
J. Clin. Microbiol. 
51 
2418 –2420 . 10.1128/JCM.00491-13 
23658254 
Turnidge J. D. Kotsanas D. Munckhof W. Roberts S. Bennett C. M. Nimmo G. R.   (2009 ). Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand. 
Med. J. Aust. 
191 
368 –373 . 19807625 
Ueda O. Tanaka S. Nagasawa Z. Hanaki H. Shobuike T. Miyamoto H.   (2015 ). Development of a novel matrix-assisted laser desorption/ionization time-of-flight mass spectrum (MALDI-TOF-MS)-based typing method to identify meticillin-resistant Staphylococcus aureus clones. 
J. Hosp. Infect. 
90 
147 –155 . 10.1016/j.jhin.2014.11.025 
25922338 
Verhoeven P. O. Grattard F. Carricajo A. Lucht F. Cazorla C. Garraud O.   (2012 ). Quantification by real-time PCR assay of Staphylococcus aureus load: a useful tool for rapidly identifying persistent nasal carriers. 
J. Clin. Microbiol. 
50 
2063 –(847)457-3314/JCM.00157-12 
22493331 
Verroken A. Defourny L. le Polain de Waroux O. Belkhir L. Laterre P. F. Delmée M.   (2016 ). Clinical impact of MALDI-TOF MS identification and rapid susceptibility testing on adequate antimicrobial treatment in sepsis with positive blood cultures. 
PLoS One 
11 :e0156299 . 10.1371/journal.pone.0156299 
27658295 
Ward M. J. Goncheva M. Richardson E. McAdam P. R. Raftis E. Kearns A.   (2016 ). Identification of source and sink populations for the emergence and global spread of the East-Asia clone of community-associated MRSA. 
Genome Biol. 
17 :160 . 10.1186/s13059-016-1022-0 
27459968 
Wu P. J. Jeyaratnam D. Tosas O. Cooper B. S. French G. L.   (2017 ). Point-of-care universal screening for meticillin-resistant Staphylococcus aureus: a cluster-randomized cross-over trial. 
J. Hosp. Infect. 
95 
245 –252 . 10.1016/j.jhin.2016.08.017 
27658666 
Yan L. Zhou J. Zheng Y. Gamson A. S. Roembke B. T. Nakayama S.   (2014 ). Isothermal amplified detection of DNA and RNA. 
Mol. Biosyst. 
10 
970 –1003 . 10.1039/c3mb70304e 
24643211 
Yeh E. C. Fu C. C. Hu L. Thakur R. Feng J. Lee L. P.   (2017 ). Self-powered integrated microfluidic point-of-care low-cost enabling (SIMPLE) chip. 
Sci. Adv. 
3 :e1501645 . 10.1126/sciadv.1501645 
28345028 
Yoshioka N. Deguchi M. Hagiya H. Yoshida H. Yamamoto N. Hashimoto S.   (2018 ). Available, bed-sided, comprehensive (ABC) score to a diagnosis of Methicillin-resistant Staphylococcus aureus infection: a derivation and validation study. 
BMC Infect. Dis. 
18 :19 . 10.1186/s12879-017-2919-2 
29310586 
Zhang T. Ding J. Rao X. Yu J. Chu M. Ren W.   (2015 ). Analysis of methicillin-resistant Staphylococcus aureus major clonal lineages by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry (MALDI-TOF MS). 
J. Microbiol. Methods 
117 
122 –127 . 10.1016/j.mimet.2015.08.002 
26253802 
Zhu W. Sieradzki K. Albrecht V. McAllister S. Lin W. Stuchlik O.   (2015 ). Evaluation of the Biotyper MALDI-TOF MS system for identification of Staphylococcus species. 
J. Microbiol. Methods 
117 
14 –17 . 10.1016/j.mimet.2015.07.014 
26183765


{'source': 'PubMedDataset'}